Literature DB >> 32307752

Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours - SMARCB1 and beyond.

P D Johann1,2,3.   

Abstract

Mutations in chromatin remodelling genes occur in approximately 25% of all human tumours (Kadoch et al. Nat Genet 45: 592-601, 2013). The spectrum of alterations is broad and comprises single nucleotide variants, insertion/deletions and more complex structural variations. The single most often affected remodelling complex is the SWI/SNF complex (SWItch/sucrose non-fermentable). In the field of paediatric neuro-oncology, the spectrum of affected genes implicated in epigenetic remodelling is narrower with SMARCB1 and SMARCA4 being the most frequent. The low mutation frequencies in many of the SWI/SNF mutant entities underline the fact that perturbed chromatin remodelling is the most salient factor in tumourigenesis and could thus be a potential therapeutic opportunity. Here, I review the genetic basis of aberrant chromatin remodelling in paediatric brain tumours and discuss their impact on the epigenome in the respective entities, mainly medulloblastomas and rhabdoid tumours.
© 2020 British Neuropathological Society.

Entities:  

Keywords:  AT/RT; Medulloblastoma; SMARCA4; SMARCB1; SWI/SNF

Mesh:

Substances:

Year:  2020        PMID: 32307752     DOI: 10.1111/nan.12616

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  1 in total

1.  Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors.

Authors:  Rajiv Pathak; Francesca Zin; Ganjam V Kalpana; Martin Hasselblatt; Christian Thomas; Susanne Bens; Tenzin Gayden; Jason Karamchandani; Roy W Dudley; Karolina Nemes; Pascal D Johann; Florian Oyen; Uwe Kordes; Nada Jabado; Reiner Siebert; Werner Paulus; Marcel Kool; Michael C Frühwald; Steffen Albrecht
Journal:  Acta Neuropathol       Date:  2021-05-18       Impact factor: 17.088

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.